Toro Neurovascular, Kaneka Forge U.S. Distribution Partnership

Toro Neurovascular has devised an exclusive distribution partnership with Kaneka Medical America for the former’s novel neurovascular catheter portfolio in the U.S. market, pending regulatory clearance.

“Partnering with Kaneka accelerates our mission to equip physicians with tools that make the most challenging neurovascular procedures more predictable and controlled,” Toro Neurovascular CEO Hyung Posalit said. “Kaneka’s commercial infrastructure and shared commitment to clinical excellence make them an ideal partner to bring our technology to market swiftly and at scale.”

The collaboration brings Toro’s next-generation catheter platform—engineered for superior trackability, distal support, and stability during complex interventions—to U.S. clinicians treating ischemic and hemorrhagic stroke. Toro’s catheter platform is designed to address unmet clinical needs with a focus on performance, deliverability, and versatility across various neurovascular interventions.

“Toro’s catheter technologies complement and strengthen our existing neurovascular portfolio, giving us the opportunity to offer a broader spectrum of solutions to patients suffering from neurovascular disease,” Kaneka Medical America President Ken Toda stated. “Together, we aim to deliver innovations that help improve procedural precision and patient care.”

Kaneka Medical America Chief Strategy Officer Rob Abrams added, “Our partnership with Toro reflects Kaneka’s culture of innovation and shared commitment to lasting impact in neurovascular care.”

To strengthen its commercialization efforts, Toro has appointed Marc Paris as chief commercial officer. Paris brings more than two decades of leadership in medical device commercialization and will oversee market launch strategy in collaboration with Kaneka.

“Joining Toro Neurovascular at this exciting time, especially with our partnership with Kaneka, is a tremendous opportunity,” Paris said. “Toro’s engineering team has developed a technology that truly advances the standard of neurovascular catheter design.”

Toro Neurovascular develops high-performance technologies for treating neurovascular disease. Headquartered in Irvine, Calif., the company combines clinical insight and advanced engineering to enhance patient outcomes worldwide.

Kaneka Corporation is a global leader in healthcare innovation, with an expanding neurovascular presence. The company aims to provide life-saving medical technologies that improve patient care and quality of life.